Allarity Therapeutics, Inc. (ALLR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Allarity Therapeutics, Inc. in 2026. The next earnings report is expected on November 12, 2026.
Allarity Therapeutics, Inc. beat consensus estimates in its latest earnings report, with a loss per share of $0.21 versus an estimated loss of $0.25, while revenue met forecasts at $0.00. In the prior report, both EPS and revenue also came in ahead of expectations.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
